NCT06798246

HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

Hematoxylin-eosin Staining-based Tumor Microenvironment Subtype System Adjuvant Therapeutic Selection for Locally Advanced Upper Tract Urothelial Carcinoma After Radical Surgery：A Perspective Cohort Study

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.

Conditions

• Upper Tract Urothelial Carcinoma

Interventions

Type	Name	Description
DRUG	Chemotherapy	Gemicitabin and cisplatin
DRUG	Immunotherapy	PD-1/PD-L1
DRUG	ADC	ADC drug like RC48
DRUG	Chemotherapy combined with immunotherapy	Chemotherapy combined with immunotherapy

Timeline

• Start date: 2025-02-01
• Primary completion: 2027-01-01
• Completion: 2030-01-01
• First posted: 2025-01-29
• Last updated: 2025-01-29